Based on the results that EPHA1, EPHA2 and EFNA1 are differentially expressed in metastatic compared to primary tissue, the EPH kinases and/or their ligands represent attractive candidates for a targeted treatment of metastatic ccRCC. Here, EPHA2 is linked to nonpapillary renal cell carcinoma.